Dr Reddy’s executive reports 8,450-share holding

DR REDDYS LABORATORIES LTD executive Patrick Rudolf Aghanian, Head - Europe Generics, filed an initial insider ownership report.

Accepted by SEC EDGAR 04/01/2026 - 01:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DR REDDYS LABORATORIES LTD executive Patrick Rudolf Aghanian, Head - Europe Generics, filed an initial insider ownership report. The filing shows direct beneficial ownership of 8,450 Equity Shares underlying ADRs, with no reported purchases or sales associated with this filing.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider AGHANIAN PATRICK RUDOLF

Role Head - Europe Generics

Type	Security	Shares	Price	Value
Holding	Equity Shares underlying ADRs	--	--	--

Holdings: Equity Shares underlying ADRs — 8,450 shares (Direct)

Key Figures

Equity shares owned: 8,450 Equity Shares underlying ADRs

1 metrics

Equity shares owned 8,450 Equity Shares underlying ADRs Direct beneficial ownership reported on Form 3

Key Terms

Form 3, Equity Shares underlying ADRs, beneficial ownership

3 terms

Form 3 regulatory

"filed an initial insider ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Equity Shares underlying ADRs financial

"direct beneficial ownership of 8,450 Equity Shares underlying ADRs"

beneficial ownership financial

"serving as an initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the DR REDDYS (RDY) Form 3 filing disclose for Patrick Rudolf Aghanian?

The Form 3 shows that Patrick Rudolf Aghanian, Head - Europe Generics, directly holds 8,450 Equity Shares underlying ADRs of DR REDDYS LABORATORIES LTD. It is an initial ownership report, not a record of new share purchases or sales.

Is the RDY Form 3 filing reporting a new insider trade by Patrick Rudolf Aghanian?

No, the RDY Form 3 does not report a new trade. It records Patrick Rudolf Aghanian’s existing direct ownership of 8,450 Equity Shares underlying ADRs, serving as an initial statement of beneficial ownership rather than a buy or sell transaction.

How many DR REDDYS (RDY) shares does Patrick Rudolf Aghanian report owning?

Patrick Rudolf Aghanian reports direct beneficial ownership of 8,450 Equity Shares underlying ADRs. This figure reflects his total holdings after the reported position, with no breakdown of separate purchase or sale transactions in this filing.

What type of security is reported in the DR REDDYS (RDY) Form 3 for Patrick Rudolf Aghanian?

The Form 3 lists Equity Shares underlying ADRs as the security held by Patrick Rudolf Aghanian. These represent the underlying equity shares associated with American Depositary Receipts, reported here as his direct beneficial ownership stake in DR REDDYS LABORATORIES LTD.

Does the DR REDDYS (RDY) Form 3 indicate whether the holdings are direct or indirect?

Yes. The filing labels the 8,450 Equity Shares underlying ADRs as direct ownership, using an ownership code of “D”. There is no indication of indirect holdings through entities like trusts or partnerships in the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

AGHANIAN PATRICK RUDOLF

(Last) (First) (Middle)

SEESTRASSE 59, 8002

(Street)

ZURICH 8002

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
12/18/2025

3. Issuer Name and Ticker or Trading Symbol
DR REDDYS LABORATORIES LTD [ RDY ]

3a. Foreign Trading Symbol
[DRREDDY&500124]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head - Europe Generics

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Equity Shares underlying ADRs	8,450	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ PATRICK AGHNIAN	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)